JP2007503388A5 - - Google Patents

Download PDF

Info

Publication number
JP2007503388A5
JP2007503388A5 JP2006523903A JP2006523903A JP2007503388A5 JP 2007503388 A5 JP2007503388 A5 JP 2007503388A5 JP 2006523903 A JP2006523903 A JP 2006523903A JP 2006523903 A JP2006523903 A JP 2006523903A JP 2007503388 A5 JP2007503388 A5 JP 2007503388A5
Authority
JP
Japan
Prior art keywords
substituted
group
alkyl
hydrogen
heterocycle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006523903A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007503388A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/025683 external-priority patent/WO2005021546A1/en
Publication of JP2007503388A publication Critical patent/JP2007503388A/ja
Publication of JP2007503388A5 publication Critical patent/JP2007503388A5/ja
Pending legal-status Critical Current

Links

JP2006523903A 2003-08-22 2004-08-09 マクロファージ遊走阻止因子の阻害剤としての置換ナフチリジン誘導体、およびヒト疾患の治療におけるそれらの使用 Pending JP2007503388A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49744303P 2003-08-22 2003-08-22
PCT/US2004/025683 WO2005021546A1 (en) 2003-08-22 2004-08-09 Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases

Publications (2)

Publication Number Publication Date
JP2007503388A JP2007503388A (ja) 2007-02-22
JP2007503388A5 true JP2007503388A5 (https=) 2007-09-27

Family

ID=34272569

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006523903A Pending JP2007503388A (ja) 2003-08-22 2004-08-09 マクロファージ遊走阻止因子の阻害剤としての置換ナフチリジン誘導体、およびヒト疾患の治療におけるそれらの使用

Country Status (13)

Country Link
US (2) US20050124604A1 (https=)
EP (1) EP1656376A1 (https=)
JP (1) JP2007503388A (https=)
CN (1) CN1839133A (https=)
AR (1) AR045471A1 (https=)
AU (1) AU2004268941A1 (https=)
BR (1) BRPI0413695A (https=)
CA (1) CA2531506A1 (https=)
MX (1) MXJL06000006A (https=)
PE (1) PE20051112A1 (https=)
TW (1) TW200524928A (https=)
UY (1) UY28483A1 (https=)
WO (1) WO2005021546A1 (https=)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140679A (en) * 2001-05-24 2010-01-15 Avanir Pharmaceuticals Inhibitors of macrohage migration inhibitory factor and methods for identifying the same
TW200418829A (en) * 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
EP1861407A1 (en) * 2005-03-24 2007-12-05 Avanir Pharmaceuticals Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors
GB0605689D0 (en) * 2006-03-21 2006-05-03 Novartis Ag Organic compounds
US8048892B2 (en) 2006-12-18 2011-11-01 Amgen Inc. Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
EP2111399A2 (en) 2006-12-18 2009-10-28 Amgen Inc. Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
EP2155680B1 (en) 2007-04-18 2013-12-04 Amgen, Inc Indanone derivatives that inhibit prolyl hydroxylase
EP2142509B1 (en) 2007-04-18 2013-12-04 Amgen, Inc Quinolones and azaquinolones that inhibit prolyl hydroxylase
US8097620B2 (en) 2007-05-04 2012-01-17 Amgen Inc. Diazaquinolones that inhibit prolyl hydroxylase activity
ES2389063T3 (es) 2007-05-04 2012-10-22 Amgen, Inc Derivados de tienopiridina y tiazolopiridina que inhiben la actividad prolil hidroxilasa
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
US9540322B2 (en) 2008-08-18 2017-01-10 Yale University MIF modulators
TW201120037A (en) * 2009-10-26 2011-06-16 Sunesis Pharmaceuticals Inc Compounds and methods for treatment of cancer
EP2592933B1 (en) * 2010-07-16 2017-04-05 Anderson Gaweco Mif inhibitors and their uses
GB2497476B (en) * 2010-09-06 2018-01-10 Guangzhou Inst Biomed & Health Amide Compounds
US9133164B2 (en) * 2011-04-13 2015-09-15 Innov88 Llc MIF inhibitors and their uses
CN103360388B (zh) * 2012-04-10 2017-11-14 江苏先声药业有限公司 5‑氨基‑1，4‑二氢‑1，8‑萘啶衍生物及其药物组合物和用途
US9617212B2 (en) 2013-12-17 2017-04-11 Controlled Chemicals, Inc. Isoindolin-1-ones as macrophage migration inhibitory factor (MIF) inhibitors
US20230322804A1 (en) * 2016-07-13 2023-10-12 bioMérieux Reagents for reversibly protecting biological molecules
WO2018119183A2 (en) 2016-12-22 2018-06-28 Amgen Inc. Kras g12c inhibitors and methods of using the same
EA201992781A1 (ru) 2017-05-22 2020-04-01 Эмджен Инк. Ингибиторы g12c kras и способы их применения
MA50077A (fr) 2017-09-08 2020-07-15 Amgen Inc Inhibiteurs de kras g12c et leurs procédés d'utilisation
CN107556309B (zh) * 2017-09-11 2020-12-01 浙江永宁药业股份有限公司 多取代四氢萘啶类化合物的药物用途及其制备方法
WO2019213516A1 (en) 2018-05-04 2019-11-07 Amgen Inc. Kras g12c inhibitors and methods of using the same
ES2995514T3 (en) 2018-05-04 2025-02-10 Amgen Inc Kras g12c inhibitors and methods of using the same
EP3790886B1 (en) 2018-05-10 2024-06-26 Amgen Inc. Kras g12c inhibitors for the treatment of cancer
ES2938987T3 (es) 2018-06-01 2023-04-18 Amgen Inc Inhibidores de KRAS G12c y métodos de uso de los mismos
US20190375749A1 (en) * 2018-06-11 2019-12-12 Amgen Inc. Kras g12c inhibitors and methods of using the same
ES3060664T3 (en) 2018-06-12 2026-03-27 Amgen Inc Kras g12c inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer
CN112654621B (zh) 2018-06-27 2024-05-14 百时美施贵宝公司 可作为t细胞活化剂的经取代萘啶酮化合物
PT3814347T (pt) * 2018-06-27 2023-07-18 Bristol Myers Squibb Co Compostos de naftiridinona úteis como ativadores de células t
JP7516029B2 (ja) 2018-11-16 2024-07-16 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
US11053226B2 (en) 2018-11-19 2021-07-06 Amgen Inc. KRAS G12C inhibitors and methods of using the same
CN111471059B (zh) * 2019-01-23 2022-12-02 药捷安康(南京)科技股份有限公司 Pde9抑制剂及其用途
SG11202109781QA (en) * 2019-03-08 2021-10-28 Transthera Sciences Nanjing Inc Uses of phosphodiesterase inhibitors
EP3738593A1 (en) 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
NZ782284A (en) 2019-05-21 2024-11-29 Amgen Inc Solid state forms
AR119821A1 (es) 2019-08-28 2022-01-12 Bristol Myers Squibb Co Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
EP4081522A1 (en) 2019-12-23 2022-11-02 Bristol-Myers Squibb Company Substituted piperazine derivatives useful as t cell activators
AR120823A1 (es) 2019-12-23 2022-03-23 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos útiles como activadores de células t
CN114846007B (zh) 2019-12-23 2024-11-22 百时美施贵宝公司 可用作t细胞激活剂的经取代的喹唑啉基化合物
AU2021358123A1 (en) 2020-10-05 2023-06-08 Enliven Inc. 5- and 6-azaindole compounds for inhibition of bcr-abl tyrosine kinases
WO2022093817A1 (en) * 2020-10-26 2022-05-05 Yale University Macrophage migration inhibitory factor inhibitors, and methods of making and using same

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4324893A (en) * 1979-04-18 1982-04-13 American Home Products Corporation 4-Amino-3-carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives
US4299814A (en) * 1979-05-25 1981-11-10 Monsanto Company Radioimmunoassay of MIF
US4284768A (en) * 1980-07-02 1981-08-18 American Home Products Corporation 1,2-Dihydro-4-amino-2-oxo-3-quinoline-carboxylic acid derivatives
GB2154592A (en) 1984-02-22 1985-09-11 Wellcome Found Cloning of a malarial gene
US5700447A (en) * 1992-05-21 1997-12-23 The Picowder Institute For Medical Research Methods and materials for the diagnosis and treatment of conditions such as stroke
US5801200A (en) * 1984-03-19 1998-09-01 The Picower Institute For Medical Research Methods and materials for the diagnosis and treatment of conditions such as stroke
US5733933A (en) * 1984-03-19 1998-03-31 The Picower Institute For Medical Research Methods and materials for the diagnosis and treatment of conditions such as stroke
US5733524A (en) * 1984-03-19 1998-03-31 The Picower Institute For Medical Research Methods and materials for the diagnosis and treatment of conditions such as stroke
US5869534A (en) 1992-05-21 1999-02-09 The Picower Institute For Medical Research Glycosylation of lipids and lipid-containing particles, and diagnostic and therapeutic methods and materials derived therefrom
AU592753B2 (en) 1984-05-24 1990-01-25 Ciba-Geigy Ag Lymphokine in pure foem, novel monoclonal antibodies hybridoma cell lines, processes and applications
US4708937A (en) * 1984-10-15 1987-11-24 Brigham & Women's Hospital Purified migration inhibitory factor also having colony stimulating factor activity
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GB8602626D0 (en) * 1986-02-04 1986-03-12 Ciba Geigy Ag Neurite-promoting factor
ES2052602T3 (es) * 1986-10-03 1994-07-16 Ciba Geigy Ag Nuevos peptidos afines a las linfocinas.
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
FI82144C (fi) * 1989-03-22 1991-01-10 Wallac Oy Foerfarande foer samtidig bestaemning av flera ligander.
GB8915414D0 (en) * 1989-07-05 1989-08-23 Ciba Geigy Novel cytokines
US5328990A (en) * 1991-04-26 1994-07-12 The United States Of America As Represented By The Department Of Health And Human Services Isolation of macrophage migration inhibition factor from ocular lens
US5352660A (en) * 1991-10-31 1994-10-04 Mount Sinai Hospital Corporation Method for assaying for a substance that affects a SH2-phosphorylated ligand regulatory system
US5624804A (en) * 1991-12-20 1997-04-29 The Rockefeller University Immunochemical detection of In vivo advanced glycosylation end products
US6645493B1 (en) * 1993-05-17 2003-11-11 The Picower Institute For Medical Research Composition containing anti-MIF antibody
DE69435303D1 (de) 1993-05-17 2010-09-02 Cytokine Pharmasciences Inc Er behandlung von krankheiten bei denen eine cytok
US6774227B1 (en) 1993-05-17 2004-08-10 Cytokine Pharmasciences, Inc. Therapeutic uses of factors which inhibit or neutralize MIF activity
US5650295A (en) * 1995-06-02 1997-07-22 Human Genone Sciences, Inc. Macrophage migration inhibitory factor-3
US6420188B1 (en) * 1996-02-16 2002-07-16 The Picower Institute For Medical Research Screening assay for the identification of inhibitors for macrophage migration inhibitory factor
US6492428B1 (en) 2000-07-26 2002-12-10 The Picower Institute For Medical Research Compounds having MIF antagonist activity
WO1997039326A2 (en) 1996-04-18 1997-10-23 Ariad Pharmaceuticals, Inc. In vitro fluorescence polarization assay
US5883224A (en) * 1996-04-19 1999-03-16 Cytokine Sciences, Inc. Characterization of transfer factors and methods of use
JPH1171351A (ja) * 1997-08-29 1999-03-16 Ss Pharmaceut Co Ltd 置換キノロン誘導体及びこれを含有する医薬
US6413939B1 (en) * 1997-10-31 2002-07-02 The Picower Institute For Medical Research Inducible phosphofructokinase and the Warburg effect
DE69811724T2 (de) 1997-12-05 2003-10-16 Pharmacia & Upjohn Co., Kalamazoo Fluoreszenz-basierte hts-(high throughput screening)assayverfahren für proteinkinase und phosphatase
EP1101106A4 (en) * 1998-07-28 2006-05-03 Bd Biosciences Systems And Rea ARRANGEMENT AND METHOD FOR THE TEST FOR CELL MOBILITY
US6214343B1 (en) * 1999-05-24 2001-04-10 Ophidian Pharmaceuticals, Inc. Prevention and treatment of necrotizing enterocolitis
AU778042B2 (en) * 1999-10-19 2004-11-11 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2001032606A1 (en) * 1999-10-29 2001-05-10 The Picower Institute For Medical Research Compounds having mif antagonist activity
EP1345603A4 (en) * 2000-12-20 2004-09-08 Merck & Co Inc (HALO-BENZO-CARBONYL) HETEROCYCLO-CONDENSED PHENYL-P38-KINASE INHIBITING AGENTS
MY140679A (en) * 2001-05-24 2010-01-15 Avanir Pharmaceuticals Inhibitors of macrohage migration inhibitory factor and methods for identifying the same
JP4117462B2 (ja) * 2001-07-03 2008-07-16 株式会社大塚製薬工場 ナフチリジンおよびキノリン誘導体
US6822097B1 (en) * 2002-02-07 2004-11-23 Amgen, Inc. Compounds and methods of uses
CN1675154A (zh) * 2002-06-07 2005-09-28 科蒂科股份有限公司 抑制巨噬细胞移动抑制因子(mif)的细胞因子或生物活性的萘衍生物
TW200418829A (en) * 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same

Similar Documents

Publication Publication Date Title
JP2007503388A5 (https=)
JP2010510976A5 (https=)
RU2344123C9 (ru) 3,4-дизамещенные циклобутен-1,2-дионы как лиганды схс-хемокинового рецептора
JP4669564B2 (ja) ２−イミノ−チアゾリジン−４−オン誘導体の製造のための新規な方法
JP2019520402A5 (https=)
JP2006507355A5 (https=)
JP2008510770A5 (https=)
JP2014518543A5 (https=)
JP2005500266A5 (https=)
JP2006516143A5 (https=)
JP2018501285A5 (https=)
JP2014513704A5 (https=)
JP2009545611A5 (https=)
JP2009515872A5 (https=)
JP2008506644A5 (https=)
JP2005526076A5 (https=)
JP2015531371A5 (https=)
JP2010504908A5 (https=)
JP2009524691A5 (https=)
JP2004524340A5 (https=)
JP2002534519A5 (https=)
JP2004535447A5 (https=)
JP2015502387A5 (https=)
JP2012532112A5 (https=)
JP2007516180A5 (https=)